Evaluation and treatment of erectile dysfunction in men with diabetes mellitus

Mayo Clinic Proceedings

Volumn 77, Issue 3, 2002, Pages 276-282

  Dey, Jayant ^a   Shepherd, Mark Devin ^a  

^a Endocrinology Consultants PLLC   (United States)

Author keywords

CAD = coronary artery disease; cGMP = cyclic guanosine monophosphate; ED = erectile dysfunction; NO = nitric oxide; NOS = NO synthase; PDE5 = type 5 cGMP phosphodiesterase

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; APOMORPHINE; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLONIDINE; DIGOXIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; INTERMEDIN; MOXISYLYTE; NICOTINE; NITRIC OXIDE; OPIATE DERIVATIVE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL AFFECTING AGENT; PROSTAGLANDIN E1; SILDENAFIL; SPASMOLYTIC AGENT; TADALAFIL; THIAZIDE DIURETIC AGENT; TRAZODONE; VARDENAFIL; YOHIMBINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ERECTILE DYSFUNCTION; EVALUATION; HUMAN; HYPOGONADISM; IMPOTENCE; MALE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THYROID DISEASE;

EID: 0036183016     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.3.276     Document Type: Article

References (43)

1. The prevalence of diabetic impotence
2. The natural history of impotence in diabetic men
3. Prevalence of self-reported erectile dysfunction in people with long-term IDDM
4. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study
5. Nitric oxide: A physiologic mediator of penile erection
6. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro
7. Impotence
8. Integrative erectile biology: The effects of age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction
9. Androgen maintenance of erectile function in the rat penis
10. Changes in erectile responsiveness during androgen replacement therapy
11. Vascular factor in erectile failure among diabetics
12. Erectile dysfunction in diabetic men: The neurological factor revisited
13. Diabetes mellitus increases nitric oxide synthase in penises but not in major pelvic ganglia of rats
14. Reduction in penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction
15. Gonadal dysfunction in diabetic men with organic impotence
16. Impotence in diabetic men
17. Process of care model for the management of erectile dysfunction in the primary care setting
18. Shared care management: The primary care perspective
19. Risk factors for impotence
20. Oral sildenafil in the treatment of erectile dysfunction
21. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial
22. Viagra® (sildenafil citrate): Efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes
23. The first study of sildenafil for erectile dysfunction in men with type 2 diabetes mellitus
24. Impotence in medical clinic outpatients
25. The calculation of bioavailable testosterone
26. A pragmatic approach to sexual dysfunction in diabetic men: Psychosexual counselling
27. Sildenafil citrate for treatment of erectile dysfunction is similarly effective in men with type 1 or type 2 diabetes mellitus
28. Safety and tolerability of sildenafil citrate for treatment of erectile dysfunction in men with type 1 and type 2 diabetes mellitus
29. Use of sildenafil (Viagra) in patients with cardiovascular disease
30. The management of impotence in diabetic men by vacuum tumescence therapy
31. Successful non-invasive management of erectile impotence in diabetic men
32. Treatment of male erectile dysfunction using the active vacuum assist device
33. Twelve-month comparison of two treatments for erectile dysfunction: Self-injection versus external vacuum devices
34. Treatment of men with erectile dysfunction with transurethral alprostadil
35. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
36. Salvage of sildenafil non-responder: The role of locally delivered therapies
37. Intracavernous self-injection pharmacotherapy program: Analysis of results and complications
38. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction
39. Oral phentolamine as treatment for erectile dysfunction
40. Trazodone, a double blind trial for treatment of erectile dysfunction
41. Overview of penile implants
42. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections